CompletedHealthcare4 November 2021

iBio, Inc. to acquire College Station Investors LLC

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
iBio, Inc.
Target
College Station Investors LLC
Deal value
USD 28,750,000
Announced
4 November 2021
Status
Completed
Sector
Healthcare
Country
United States
Consideration
cash, shares
What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update
  1. CompletedClosed

    iBio, Inc. completes acquisition of College Station Investors LLC

    Item 1.01. Entry into a Material Definitive Agreement. On November 1, 2021, iBio, Inc. (the “ Company ”) and its subsidiary, iBio CDMO LLC (“ iBio CDMO ”, and collectively with the Company, the “ Purchaser ”) entered into a series of agreements (the “ Transaction ”) with College Station Investors LLC (“ College Station ”), and Bryan Capital Investors LLC, each affiliates of Eastern Capital Limited

    Source

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

30 June 2026Firm intentionHealthcare

Public Company Management Corporation to acquire Physicians Capital Management Corporation

Public Company Management Corporation has agreed to acquire Physicians Capital Management Corporation in a strategic acquisition within the healthcare sector. The transa…

Buyer
Public Company Management Corporation
Target
Physicians Capital Management Corporation
Deal value
Not disclosed
Deal type
strategic acquisition

Buyer history

iBio, Inc.

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive